Are Krebs Biochemicals & Industries Ltd latest results good or bad?

Krebs Biochemicals & Industries Ltd continues to face significant operational challenges, as evidenced by its latest financial results for Q4 FY26. The company reported net sales of ₹6.81 crores, which reflects an 11.64% year-on-year growth compared to ₹6.10 crores in Q4 FY25. However, this growth is overshadowed by a sequential decline of 6.33% from ₹7.27 crores in Q3 FY26, indicating revenue volatility. The net loss for the quarter was ₹2.34 crores, which represents a 25.24% improvement from the previous quarter's loss of ₹3.13 crores, yet it remains significantly worse than the ₹8.27 crores loss reported in Q4 FY25. The company's PAT margin stood at -34.36%, an improvement from -43.05% in the prior quarter, but still highlights ongoing profitability challenges. Krebs Biochemicals has a negative book value of ₹-67.83 per share, reflecting a troubling financial position with shareholder equity at ₹-146.24 crores. The company has been experiencing persistent cash burn, with negative operating cash flows recorded in four of the last five years. The current ratio of 0.10 indicates severe working capital stress, raising concerns about the company's ability to meet short-term obligations. The overall financial performance suggests that while there are some signs of year-on-year revenue growth, the underlying operational issues, including chronic losses and a precarious balance sheet, continue to pose significant risks. The company saw an adjustment in its evaluation, reflecting the ongoing challenges it faces in achieving commercial viability.